Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations

OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare disease that is currently considered a low-grade neoplasm with metastatic potential and variable progression. Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Bras Pneumol
Main Authors: Freitas, Carolina Salim Gonçalves, Baldi, Bruno Guedes, Araújo, Mariana Sponholz, Heiden, Glaucia Itamaro, Kairalla, Ronaldo Adib, Carvalho, Carlos Roberto Ribeiro
Formato: Artigo
Idioma:Inglês
Publicado em: Sociedade Brasileira de Pneumologia e Tisiologia 2015
Assuntos:
Case Series
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4541764/
https://ncbi.nlm.nih.gov/pubmed/26176526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/S1806-37132015000004553
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados